AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Budesonide cuts psychiatric symptoms in Crohn's Disease. (Vs. Prednisolone).
SAN FRANCISCO -- Psychiatric symptoms are only half as likely to occur in patients with Crohn's disease treated with oral budesonide, compared with prednisolone, Dr. William J. Sanborn reported at the annual Digestive Disease Week.
He presented a pooled analysis of one 16-week and four 8-week clinical trials in which 772 patients with active Crohn's disease were randomized to budesonide 9 mg/day, prednisolone 40 mg/day with a taper, or placebo. The efficacy end points were previously reported: Budesonide was as effective as and was better tolerated than prednisolone and is now Food and Drug Administration-approved as a first-line treatment for mild to moderate Crohn's disease.
The new analysis, sponsored by AstraZeneca, was undertaken to examine the psychiatric side effects of budesonide and prednisolone. It ...